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Despite known limitations of algorithm based designs (e.g.
3+3) they are favoured for use in dose finding studies due
to simplicity and familiarity. Bayesian adaptive designs can
overcome these limitations as they’re more efficient and
substantially more accurate.
EffTox is such a design which aims to determine the
optimal, tolerable and efficacious dose. We implemented
this design in a multicentre clinical trial of a novel TKI
in combination with chemotherapy to treat chronic
myeloid leukaemia. It is expected that the probability of
efficacy may increase to a maximum then level off, thus
higher doses of the combination may not result in
greater efficacy. Given this non-monotone dose-response
relationship, solely toxicity based dose-finding designs
are not appropriate. In addition EffTox has demon-
strated favourable properties of exposing fewer patients
to potentially toxic and inefficacious doses, allocates
more patients to the optimal dose and results in less
dose-modifying toxicities in a subsequent phase-II/III
trial.
A Bayesian analysis is conducted using a bivariate bin-
ary probability model with prior probabilities elicited
from clinicians. Dose recommendations are based on an
efficacy-toxicity trade-off contour. Operating character-
istics were explored via simulations of various scenarios
using readily available EffTox software. The design has
satisfactory operational characteristics and is flexible to
be adapted trial specific requirements.
Challenges in implementing this design included over-
coming clinicians’ preconceptions, obtaining clinician
consensus to enable development of the desirability
trade-off contour and educating committees to secure
funding. Overcoming these challenges allows design of
robust dose-finding trials establishing an optimal, rather
than sub-optimal dose.
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